Six biomarkers (HOTAIR, ISM2, KRTAP3-1, SPDYC, LY6G6F, and NKD1) found no drug available in LINCS1000 (Subramanian et al., 2017) to modulate their expression, and these constitute potential novel targets for drug discovery against metastatic transition in CRC. The gene discussed is NKD1; the disease is colorectal carcinoma.